Allakos Inc. (ALLK)

NASDAQ: ALLK · IEX Real-Time Price · USD
1.230
-0.080 (-6.11%)
At close: Mar 18, 2024, 4:00 PM
1.220
-0.010 (-0.81%)
Pre-market: Mar 19, 2024, 5:47 AM EDT
-6.11%
Market Cap 114.59M
Revenue (ttm) n/a
Net Income (ttm) -185.70M
Shares Out 87.87M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 697,814
Open 1.280
Previous Close 1.310
Day's Range 1.200 - 1.280
52-Week Range 1.000 - 5.640
Beta 0.82
Analysts Buy
Price Target 3.63 (+195.12%)
Earnings Date Mar 14, 2024

About ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 19, 2018
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ALLK stock is "Buy." The 12-month stock price forecast is $3.63, which is an increase of 195.12% from the latest price.

Price Target
$3.63
(195.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolif...

4 days ago - GlobeNewsWire

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages –

21 days ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ...

5 weeks ago - Accesswire

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

–  Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells –

5 weeks ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK).  Such investors are advised to contac...

5 weeks ago - PRNewsWire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (...

5 weeks ago - Accesswire

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (...

6 weeks ago - Accesswire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (...

6 weeks ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (...

7 weeks ago - Accesswire

Allakos to stop further development of skin disease drug, plans job cuts

Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.

2 months ago - Reuters

Allakos Announces a Restructuring to Focus on Development of AK006

SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolifera...

2 months ago - GlobeNewsWire

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...

4 months ago - GlobeNewsWire

Allakos Appoints Neil Graham to its Board of Directors

SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on imm...

7 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BLFSKZRTCRT
7 months ago - Benzinga

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...

7 months ago - GlobeNewsWire

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on imm...

8 months ago - GlobeNewsWire

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activa...

10 months ago - GlobeNewsWire

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on imm...

10 months ago - GlobeNewsWire

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolifer...

11 months ago - GlobeNewsWire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolif...

1 year ago - GlobeNewsWire

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent ...

1 year ago - GlobeNewsWire

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer's 37th Annual Meeting

– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including t...

1 year ago - GlobeNewsWire

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and i...

1 year ago - GlobeNewsWire

Alkermes, Allakos See Activist Action

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Other symbols: ALKS
1 year ago - Market Watch

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Top-line Phase 2b results expected in the second half of 2023 Top-line Phase 2b results expected in the second half of 2023

1 year ago - GlobeNewsWire